Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 25, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on September 25, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 40 Common Stock at $470.56 ($18,822) on September 25, 2026; holds 333,903 after (Indirect).
- Open-market sale: disposed of 200 Common Stock at $471.84 ($94,368) on September 25, 2026; holds 333,703 after (Indirect).
- Open-market sale: disposed of 800 Common Stock at $472.89 ($378,309) on September 25, 2026; holds 332,903 after (Indirect).
- Open-market sale: disposed of 543 Common Stock at $474.15 ($257,462) on September 25, 2026; holds 332,360 after (Indirect).
- Open-market sale: disposed of 1,613 Common Stock at $475.28 ($766,623) on September 25, 2026; holds 330,747 after (Indirect).
- Open-market sale: disposed of 2,744 Common Stock at $476.13 ($1,306,507) on September 25, 2026; holds 328,003 after (Indirect).
- Open-market sale: disposed of 1,280 Common Stock at $477.19 ($610,805) on September 25, 2026; holds 326,723 after (Indirect).
- Open-market sale: disposed of 1,648 Common Stock at $478.18 ($788,042) on September 25, 2026; holds 325,075 after (Indirect).
- Open-market sale: disposed of 632 Common Stock at $478.95 ($302,698) on September 25, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on September 25, 2026; holds 356,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,523,635 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-25 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-09-25 | Open-market sale | Common Stock | 40 | $471 | $18.8K | 333,903 |
| 2026-09-25 | Open-market sale | Common Stock | 200 | $472 | $94.4K | 333,703 |
| 2026-09-25 | Open-market sale | Common Stock | 800 | $473 | $378.3K | 332,903 |
| 2026-09-25 | Open-market sale | Common Stock | 543 | $474 | $257.5K | 332,360 |
| 2026-09-25 | Open-market sale | Common Stock | 1,613 | $475 | $766.6K | 330,747 |
| 2026-09-25 | Open-market sale | Common Stock | 2,744 | $476 | $1.3M | 328,003 |
| 2026-09-25 | Open-market sale | Common Stock | 1,280 | $477 | $610.8K | 326,723 |
| 2026-09-25 | Open-market sale | Common Stock | 1,648 | $478 | $788.0K | 325,075 |
| 2026-09-25 | Open-market sale | Common Stock | 632 | $479 | $302.7K | 324,443 |
| 2026-09-25 | Option exercise/conversion | Stock Option | 9,500 | — | — | 356,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-25 | Option exercise/conversion (9,500 shares) |
| 2026-09-25 | Open-market sale (40 shares) |
| 2026-09-25 | Open-market sale (200 shares) |
| 2026-09-25 | Open-market sale (800 shares) |
| 2026-09-25 | Open-market sale (543 shares) |
| 2026-09-25 | Open-market sale (1,613 shares) |
| 2026-09-25 | Open-market sale (2,744 shares) |
| 2026-09-25 | Open-market sale (1,280 shares) |
| 2026-09-25 | Open-market sale (1,648 shares) |
| 2026-09-25 | Open-market sale (632 shares) |
| 2026-09-25 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.